Androstenol

Androstenol

SCHEMBL3365124

C[C@@]12C=CC[C@H]1[C@@H]1CCC3CC(O)CC[C@]3(C)[C@H]1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I3 Q14994 2/20 1.00
ALDH1A1 P00352 1/20 1.00
LMNA P02545 3/20 0.62
GPBAR1 Q8TDU6 2/20 0.62
SHBG P04278 1/20 0.62
SERPINA6 P08185 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C9 P11712 1/20 0.62
TSHR P16473 1/20 0.62
CYP2C19 P33261 1/20 0.62
HSD17B10 Q99714 1/20 0.62
KDM4E B2RXH2 1/20 0.58
MAPT P10636 1/20 0.58
MEN1 O00255 1/20 0.55
GABRP O00591 1/20 0.55
GABRD O14764 1/20 0.55
GMNN O75496 1/20 0.55
G6PD P11413 1/20 0.55
GABRA1 P14867 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Androstenol SCHEMBL3163766 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL324888 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL8817019 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL5072488 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL9543417 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL8817023 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL3163769 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL4533664 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL14360552 1.00 NR1I3 (1.00) NR1I3ALDH1A1LMNAGPBAR1SHBG
Androstenol SCHEMBL27501533 0.88 KDM4E (0.81) NR1I3ALDH1A1LMNAGPBAR1SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108289898-A In the pheromone compositions and its application method of female pigs category animal moderate stimulation reproduction 德克萨斯理工大学系统 2018-07-17 CN claimed
EP-0139554-B1 DERIVATIVES OF MURAMYL PEPTIDES AND STEROIDS HAVING MACROPHAGE ACTIVATING PROPERTIES ANVAR Agence Nationale de Valorisation de la Recherche (FR) 1989-08-02 EP claimed
US-4663311-A Derivatives of muramyl-peptides and of steroids having macrophage-activating properties TENU JEAN P (FR) 1987-05-05 US claimed
US-20240336711-A1 REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2024-10-10 US disclosed
WO-2022241129-A1 REAGENTS AND METHODS FOR ALIPHATIC CARBON—HYDROGEN BOND FUNCTIONALIZATION THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2022-11-17 WO disclosed
CN-110604754-B Pheromone composition capable of improving estrus mating rate of sows 宁波第二激素厂 2021-11-26 CN disclosed
CN-110664862-B Pheromone composition spray preparation and preparation method and application thereof 宁波第二激素厂 2021-07-30 CN disclosed
US-10908162-B2 Methods related to volatile compounds in genitourinary cancers THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-02-02 US disclosed
CN-110664862-A Pheromone composition spray preparation and preparation method and application thereof 宁波第二激素厂 2020-01-10 CN disclosed
CN-110604754-A Pheromone composition capable of improving estrus mating rate of sows 宁波第二激素厂 2019-12-24 CN disclosed
US-20190128890-A1 METHODS RELATED TO VOLATILE COMPOUNDS IN GENITOURINARY CANCERS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-05-02 US disclosed
EP-0209578-A1 METHOD USING POOLED FEMALE AXILLARY ESSENCE FROM MULTIPLE DONORS TO ALTER MENSTRUAL CYCLE TIMING MONELL CHEMICAL SENSES CENTER (US) 1987-01-28 EP disclosed
EP-0084537-B1 METHOD AND MEANS FOR REPELLING ANIMALS NORDTEND A/S (NO) 1986-10-15 EP disclosed
WO-1986004238-A1 METHOD USING POOLED FEMALE AXILLARY ESSENCE FROM MULTIPLE DONORS TO ALTER MENSTRUAL CYCLE TIMING MONELL CHEMICAL SENSES CENTER (US) 1986-07-31 WO disclosed
WO-1986004418-A1 AXILLARY ANDROSTENOL AND DEHYDROEPIANDROSTERONE AS FERTILE PERIOD ONSET INDICATORS MONELL CHEMICAL SENSES CENTER (US) 1986-07-31 WO disclosed
WO-1986004236-A1 THE USE OF MALE ESSENCE, INCLUDING ANDROSTENOL AND DEHYDROEPIANDROSTERONE SULFATE TO TREAT LUTEAL PHASE DEFECTS AND FAILURE TO OVULATE IN HUMAN FEMALES MONELL CHEMICAL SENSES CENTER (US) 1986-07-31 WO disclosed
EP-0139554-A1 Derivatives of muramyl peptides and steroids having macrophage activating properties ANVAR Agence Nationale de Valorisation de la Recherche (FR) 1985-05-02 EP disclosed
US-4451460-A WITH HUMAN STEROIDS NORDTEND A/S (NO) 1984-05-29 US disclosed
EP-0084537-A1 METHOD AND MEANS FOR REPELLING ANIMALS. NORDTEND AS (NO) 1983-08-03 EP disclosed
WO-1983000417-A1 METHOD AND MEANS FOR REPELLING ANIMALS HANSEN, HELGE 1983-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336711-A1 REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION NCF1, SHROOM3, NPM1 NR1I3 4045/4885ALDH1A1 2010/4885LMNA 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.